Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > REGULATORY
REGULATORY
- MHLW Looking into Drug Maker Payments to PAFSC Members: Shiozaki
April 24, 2015
- LDP Weighs Clinical Development Infrastructure Utilizing Patient Registry
April 24, 2015
- Council on Unapproved Drugs to Issue Development Requests Immediately In Cases of Unanimous Approval by Working Groups
April 24, 2015
- MHLW Orders Revision of Package Inserts for Plavix
April 24, 2015
- Polyethylene Glycol Has Great Unmet Medical Need: Panel
April 23, 2015
- MHLW Official Jo Hints at Possible Move-Up of Generic Roadmap
April 23, 2015
- Find Solid Candidates from Early Development Stage: MHLW’s Mori
April 23, 2015
- Ease Post-Marketing Burdens for Intractable Disease Treatments: JPMA Exec
April 22, 2015
- AMED Chief Envisages Tapping Private Funds to Fuel R&D
April 22, 2015
- Editor’s Pick: Five Healthcare News Headlines for April 6 - 19
April 20, 2015
- Govt Checks on Progress of Healthcare R&D Promotion Plan
April 20, 2015
- Govt Panel Members Call for Medication Control to Eliminate Unused Drugs
April 17, 2015
- Govt Panel to Prod Chuikyo to Revisit 14-Day Prescription Limit
April 17, 2015
- Who Will Foot the Bill for Cost-Effective Assessments?: Chuikyo Chair
April 16, 2015
- Japan Faces Imperative to Increase Biostatisticians to Boost Clinical Research Quality
April 16, 2015
- PAFSC 1st Committee to Discuss Add’l Indication for Cymbalta on April 28
April 15, 2015
- “Proper Management” Essential in Company Funding of Academic Research: MHLW Official
April 15, 2015
- PMDA Invites People with Broad Perspective from the Medical Community to Join PMDA: Chief Executive
April 15, 2015
- MHLW Official Introduces Patient ADR Reporting System
April 15, 2015
- Cost-Effectiveness Case Study to Be Reported to Chuikyo in May: Official
April 14, 2015
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…